Toate știrile / Iulie 2021

Arhivă

23 iulie 2021

3518

Cartoons tackling HIV stigma and misinformation in Italy

Italian activists have launched a new information campaign called “HIV, let’s talk about it”. The series of six cartoons aim to educate and inform the public on the topic of HIV & AIDS. Each cartoon in the series focuses on a different topic related to stigma, homophobia, ...

italiancartoon2021italycampaigninformationstigmaactivistsactivismHIVAIDSpreventiontreatmentcondoms

23 iulie 2021

2793

Number of CD4 cells and early treatment affects volume of HIV reservoirs

Experts believe that people with HIV who start antiretroviral treatment before they develop extensive immune system damage will end up with a smaller HIV reservoir in the long run - something that in turn can improve effectiveness of treatment and the quality of life of ...

2021ias 2021ias2021iasconferencehivplhivplwhvirusviral loadreservoircd4researchquality of lifearttreatment

23 iulie 2021

Tom Hayes

2808

Merck shares results of Islatravir as PrEP trial

Merck, presented the results of a Phase-II trial of islatravir, a long-acting drug, for the treatment and prevention of HIV, at the 11th International Scientific Conference IAS 2021. Participants received ISL orally once a month for 6 months. After 6 months the treatment ...

ISL2021ias2021iasias 2021merckmsdresearchstudytrialpreppre exposure prophylaxispre-exposure prophylaxispreventionislatravirhiv

22 iulie 2021

Tom Hayes

3052

IAS 2021: Phase-III results from Frontier’s long-acting Aikening (albuvirtide)

Chinese biotech company, Frontier Biotechnologies, presented the results of a Phase-III clinic trial examining their new long-acting HIV fusion inhibitor, Aikening (albuvirtide). The study into a new long-acting injectable treatment is the first new HIV drug to be developed ...

FrontierBiotech2021julyIAS 2021IAS2021IASfit biotechalbuvertideaikeningfusion inhibitorhivtreatmentinjectlong acting injectableinjectioninjectablesciencestudytrialchinaasia

22 iulie 2021

Tom Hayes

2575

IAS 202: Are people living with HIV likely to be more severely impacted by COVID-19?

During the IAS Conference on HIV Science 2021 (IAS 2021) several reports and sets of data were presented on the impact of HIV and COVID-19. Here are just three. World Health Organisation says that you're more likely to suffer severe COVID-19 if you are male; or over 65 ...

PLWHcomorbidity2021julyconferenceias 2021iasias2021WHOworld health organisationCOVIDCOVID-19coronavirusHIVPLHIVcomorbiditieshealthhospitalisationstudydata

22 iulie 2021

Tom Hayes

2808

HIV experts come together to say that HIV care needs to be more than viral load & CD4 counts

Since the advent of effective antiretroviral therapy (ART) in 1996, HIV transmission and AIDS-related mortality have decreased significantly. Despite these achievements, people living with HIV still tend to experience a poorer health and a lower quality of life. Aiming ...

mdtmultidisciplinary groupexperthollisitcholistichuman centered carejeffery lazarusquality of life2021treatmentIAS 2021HIVpeople living with hivhealthcarecare

21 iulie 2021

Tom Hayes

2778

Dapivirine vaginal ring is an effective and convenient means of HIV prevention

Findings from a study in South Africa, Uganda and Zimbabwe found that girls and young women showed a high level of adherence to both oral PrEP and a dapivirine vaginal ring - with the vaginal ring being favoured by participants. Most women showed moderate adherence to ...

Julyoral2021africasouth africaZimbabweugandavaginalringDapivirinepreppre-exposure prophylaxispre exposure prophylaxisprophylaxishivaidspreventionIAS2021iasias 2021whoworld health organisation

21 iulie 2021

3287

IAS 2021 – Update on lenacapavir, a long-lasting injectable agent to treat HIV

Lenacapavir, developed by Gilead Sciences, is an injectable long-acting agent that is currently being evaluated for its ability to treat HIV in people with multi-drug resistance (MDR) and those with no other therapy options. New data on the agent was presented at the ...

ias 20212021IAS2021conferenceLenacapavircapsidinhibitorgileadgilead scienceslong lastinglong actinginjectioninjectable

21 iulie 2021

Tom Hayes

2556

New treatment regimens for highly drug-resistant tuberculosis

A new study conducted by TB Alliance has shown that the BPaL regimen for the treatment of highly drug-resistant tuberculosis remained effective when the dosage of linezolid was reduced. Researchers also noted a decrease in side effects associated with the reduced linezolid ...

lungpretomanid2021julytuberculosislinezolidTBBPaLhealthcomorbiditiestreatmentregimenstudybedaquiline

21 iulie 2021

Tom Hayes

2895

WHO: People with HIV need to be vaccinated against COVID-19 as a matter of priority

A new report from the World Health Organisation (WHO) confirms that HIV can play a significant role in the risk of severe COVID-19. The WHO report is based on clinical surveillance of severe coronavirus outcomes in people living with HIV who were hospitalised due to COVID-19. ...

priority2021vaccinevaccinationcovidcoronaviruscovid-19hivplhivpwhivWHOworld health organisationIAS2021IASreport

1 2